Bacil Pharma loses another large holder as Shah sells 2.75% stake
Manubhai Amrutlal Shah's latest sale brings his June total to over 8%, following last week's 7.10% exit by another substantial shareholder, as the nano-cap sits on zero revenue and a market cap of ₹60 crore.
— 7 earlier stories on Bacil Pharma Ltd. →What's new
- Manubhai Amrutlal Shah sold 394,893 shares (2.75% equity) on June 23-24, cutting his holding from 12.77% to 10.02%.
- This follows a 5.57% sale earlier in June, making his total June disposal over 8%.
- Another substantial shareholder, Patel, had sold a 7.10% stake just days before.
Why this matters
For a company with zero operating revenue and a market cap of just ₹60 crore, the rapid exit of two large non-promoter holders in June signals a clear loss of confidence. Shah's stake now hovers just above the 10% substantial-holder threshold, inviting further sell-downs. The board's upcoming fundraising meet on June 26 raises the question of who will back a shell.
What we're watching
- Whether Shah cuts further below the 10% threshold in coming sessions.
- The outcome of the June 26 board meeting on fundraising options.
- Any regulatory triggers if substantial holdings drop further.
The full read
Bacil Pharma has lost another large non-promoter holder. Manubhai Amrutlal Shah sold 2.75% of the company on June 23-24, his second batch in June, taking his monthly total to over 8% and cutting his stake to 10.02%. This follows news just yesterday that another substantial shareholder, Patel, dumped 7.10% over two days. For a nano-cap reporting zero operating revenue and with a market cap of just ₹60 crore, the pace of insider selling is stark. A board meeting on June 26 to discuss fundraising sounds like an ask for capital at a company no one wants to own. With Shah now a whisker above the 10% threshold, the next move is likely more sales, not fewer.
Questions answered
- How much equity has Manubhai Amrutlal Shah sold in June 2026?
- He sold 5.57% earlier in June and another 2.75% on June 23-24, for a total of over 8% in one month. His holding has dropped from 12.77% to 10.02%.
- What is Bacil Pharma's business status?
- The company reported zero operating revenue in the latest quarter (March 2026) and has a market capitalisation of about ₹60 crore. It is a nano-cap with no active operations.
- How does this sale compare with other recent insider exits?
- Another substantial shareholder, Patel, sold a 7.10% stake earlier in June. Combined, the two large holders have sold over 8% (Shah) and 7.10% (Patel) of the company this month, signaling broad insider disengagement.
- What is the significance of Shah's holding falling to 10.02%?
- Just above the 10% substantial-holder threshold. If he sells even a small number of shares, he could drop below that mark, potentially changing disclosure obligations and reducing strategic interest in the stock.
- What is the board planning to discuss on June 26?
- The board is meeting to consider fundraising options. However, with zero revenue and a rapidly shrinking shareholder base, the viability of any capital raise is uncertain.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 25 Jun 2026 · 8:33 AM IST Bacil Pharma loses another large holder as Shah sells 2.75% stake
- 1d ago Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 1d ago Bacil Pharma board to mull fundraising options on June 26
- 7d ago Bacil Pharma proposes R&D arm, but numbers are missing
- 12d ago Another large Bacil Pharma shareholder sells 5.57% stake